Lung Cancer
Volume 62, Issue 1 , Pages 35-44 , October 2008

EGFR, TTF-1 and Mdm2 expression in stage III non-small cell lung cancer: A positive association

  • T. Berghmans

      Affiliations

    • Department of Intensive Care Unit and Thoracic Oncology, Institut Jules Bordet, ULB (Université Libre de Bruxelles), Bruxelles, Belgium
    • These authors contributed equally to this work.
    • Corresponding Author InformationCorresponding author at: Institut Jules Bordet, Rue Héger-Bordet, 1, Bruxelles 1000, Belgium. Tel.: +32 2 5413191; fax: +32 2 5343756.
    • ,
  • C. Mascaux

      Affiliations

    • Department of Intensive Care Unit and Thoracic Oncology, Institut Jules Bordet, ULB (Université Libre de Bruxelles), Bruxelles, Belgium
    • FNRS (National Fund of Scientific Research), Belgium
    • These authors contributed equally to this work.
    • ,
  • A. Haller

      Affiliations

    • Department of Pathology, Institut Jules Bordet, ULB (Université Libre de Bruxelles), Bruxelles, Belgium
    • ,
  • A.P. Meert

      Affiliations

    • Department of Intensive Care Unit and Thoracic Oncology, Institut Jules Bordet, ULB (Université Libre de Bruxelles), Bruxelles, Belgium
    • ,
  • P. Van Houtte

      Affiliations

    • Department of Radiotherapy, Institut Jules Bordet, ULB (Université Libre de Bruxelles), Bruxelles, Belgium
    • ,
  • J.P. Sculier

      Affiliations

    • Department of Intensive Care Unit and Thoracic Oncology, Institut Jules Bordet, ULB (Université Libre de Bruxelles), Bruxelles, Belgium

Received 20 November 2007 ,Revised 21 January 2008 ,Accepted 5 February 2008.

References 

  1. Graziano SL. Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer. 1997;17(Suppl. 1):S37–S58
  2. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710–1717
  3. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706–714
  4. Andre F, Grunenwald D, Pignon JP, Dujon A, Pujol JL, Brichon PY, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol. 2000;18:2981–2989
  5. Bollen EC, Theunissen PH, van Duin CJ, Drenth BM, van Noord JA, Blijham GH. Clinical significance of intranodal and extranodal growth in lymph node metastases of non-small cell lung cancer. Scand J Thorac Cardiovasc Surg. 1994;28:97–102
  6. Inoue K, Sato M, Fujimura S, Sakurada A, Takahashi S, Usuda K, et al. Prognostic assessment of 1310 patients with non-small-cell lung cancer who underwent complete resection from 1980 to 1993. J Thorac Cardiovasc Surg. 1998;116:407–411
  7. Jassem J, Skokowski J, Dziadziuszko R, Jassem E, Szymanowska A, Rzyman W, et al. Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification. J Thorac Cardiovasc Surg. 2000;119:1141–1146
  8. Leong SS, Rocha Lima CM, Sherman CA, Green MR. The 1997 International Staging System for non-small cell lung cancer: have all the issues been addressed?. Chest. 1999;115:242–248
  9. Vansteenkiste JF, De Leyn PR, Deneffe GJ, Stalpaert G, Nackaerts KL, Lerut TE, et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group. Ann Thorac Surg. 1997;63:1441–1450
  10. Berghmans T, Lafitte JJ, Thiriaux J, VanHoutte P, Lecomte J, Efremidis A, et al. Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy. Lung Cancer. 2004;45:339–348
  11. Sculier JP, Paesmans M, Ninane V, Giner V, Bureau G, Lafitte JJ, et al. Evaluation of the TN sub-staging in patients with initially unresectable stage III non-small cell lung cancer treated by induction chemotherapy. The European Lung Cancer Working Party. Lung Cancer. 1998;22:201–213
  12. Kanters SD, Lammers JW, Voest EE. Molecular and biological factors in the prognosis of non-small cell lung cancer. Eur Respir J. 1995;8:1389–1397
  13. Sculier JP, Paesmans M, Libert P, Bureau G, Dabouis G, Thiriaux J, et al. Facteurs pronostiques dans le cancer bronchique non à petites cellules avancé: expériences de l’European Lung Cancer Working Party. Rev Mal Respir. 1997;14:445–449
  14. D’Amico TA, Massey M, Herndon JE, Moore MB, Harpole DH. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg. 1999;117:736–743
  15. Pastorino U, Andreola S, Tagliabue E, Pezzella F, Incarbone M, Sozzi G, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol. 1997;15:2858–2865
  16. Langendijk H, Thunnissen E, Arends JW, de JJ, ten VG, Lamers R, et al. Cell proliferation and apoptosis in stage III inoperable non-small cell lung carcinoma treated by radiotherapy. Radiother Oncol. 2000;56:197–207
  17. Langendijk JA, Thunnissen FB, Lamers RJ, de Jong JM, ten Velde GP, Wouters EF. The prognostic significance of accumulation of p53 protein in stage III non-small cell lung cancer treated by radiotherapy. Radiother Oncol. 1995;36:218–224
  18. Lee TK, Horner RD, Silverman JF, Chen YH, Jenny C, Scarantino CW. Morphometric and morphologic evaluations in stage III non-small cell lung cancers. Prognostic significance of quantitative assessment of infiltrating lymphoid cells. Cancer. 1989;63:309–316
  19. Wachters FM, Wong LS, Timens W, Kampinga HH, Groen HJ. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer. 2005;50:211–219
  20. Broermann P, Junker K, Brandt BH, Heinecke A, Freitag L, Klinke F, et al. Trimodality treatment in Stage III nonsmall cell lung carcinoma: prrognostic impact of K-ras mutations after neoadjuvant therapy. Cancer. 2002;94:2055–2062
  21. Spierings D, de Vries E, Timens W, Groen HJ, Boezen H, de Jong J. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res. 2003;9:3397–3405
  22. Uramoto H, Osaki T, Inoue K, Taga S, Takenoyama M, Hanagiri T, et al. Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patients. Eur J Cancer. 1999;35:1462–1465
  23. Berghmans T, Meert AP, Martin B, Ninane V, Sculier JP. Prognostic role of EGF-Receptor in stage III non-small cell lung cancer. Eur Respir. 2005;J 25(2):329–335
  24. Berghmans T, Mascaux C, Martin B, Ninane V, Sculier JP. Prognostic role of p53 in stage III non-small cell lung cancer. Anticancer Res. 2005;25:2385–2389
  25. Berghmans T, Mascaux C, Martin B, Ninane V, Sculier JP. Prognostic role of thyroid transcription factor-1 in stage III non-small cell lung cancer. Lung Cancer. 2006;52:219–224
  26. Eymin B, Gazzeri S, Brambilla C, Brambilla E. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors. Oncogene. 2002;21:2750–2761
  27. Berghmans T, Paesmans M, Mascaux C, Martin B, Meert AP, Haller A, et al. Thyroid transcription factor 1—a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol. 2006;17:1673–1676
  28. Meert AP, Martin B, Delmotte P, Berghmans T, Lafitte JJ, Mascaux C, et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J. 2002;20:975–981
  29. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J. 2001;18:705–719
  30. Aikawa H, Sato M, Fujimura S, Takahashi H, Endo C, Sakurada A, et al. MDM2 expression is associated with progress of disease and WAF1 expression in resected lung cancer. Int J Mol Med. 2000;5:631–633
  31. Dworakowska D, Jassem E, Jassem J, Peters B, Dziadziuszko R, Zylicz M, et al. MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC). Lung Cancer. 2004;43:285–295
  32. Dworakowska D, Jassem E, Jassem J, Karmolinski A, Dworakowski R, Wirth T, et al. Clinical significance of apoptotic index in non-small cell lung cancer: correlation with p53, mdm2, pRb and p21WAF1/CIP1 protein expression. J Cancer Res Clin Oncol. 2005;131:617–623
  33. Higashiyama M, Doi O, Kodama K, Yokouchi H, Kasugai T, Ishiguro S, et al. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br J Cancer. 1997;75:1302–1308
  34. Ko JL, Cheng YW, Chang SL, Su JM, Chen CY, Lee H. MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer. Int J Cancer. 2000;89:265–270
  35. Wang YC, Lin RK, Tan YH, Chen JT, Chen CY, Wang YC. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer. J Clin Oncol. 2005;23:154–164
  36. de Jong JS, van Diest PJ, van d V, Baak JP. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J Pathol. 1998;184:53–57
  37. Tanaka H, Yanagisawa K, Shinjo K, Taguchi A, Maeno K, Tomida S, et al. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res. 2007;67:6007–6011
  38. Makoto O, Tomofumi I, Yutaka Y. Unique cellular features in atypical adenomatous hyperplasia of the lung: ultrastructural evidence of its cytodifferentiation. Ultrastruct Pathol. 2001;25:367–373
  39. Awaya H, Takeshima Y, Furonaka O, Kohno N, Inai K. Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung. J Clin Pathol. 2005;58:1076–1080
  40. Meert AP, Verdebout JM, Martin B, Ninane V, Feoli F, Sculier JP. Epidermal growth factor receptor expression in pre-invasive and early invasive bronchial lesions. Eur Respir J. 2003;21:611–615
  41. Rusch V, Klimstra D, Linkov I, Dmitrovsky E. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res. 1995;55:1365–1372
  42. Martin B, Verdebout JM, Mascaux C, Paesmans M, Rouas G, Verhest A, et al. Expression of p53 in preneoplastic and early neoplastic bronchial lesions. Oncol Rep. 2002;9:223–229
  43. Brambilla E, Gazzeri S, Lantuejoul S, Coll JL, Moro D, Negoescu A, et al. p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer. Clin Cancer Res. 1998;4:1609–1618
  44. Mascaux C, Haller A, Martin B, Feoli F, Ninane V, Sculier JP. Early lung carcinogenesis: MDM2 expression in bronchial preneoplastic lesions and its correlation with p53. Lung Cancer. 2005;49(Supplement 2):S5
  45. Graziano SL, Tatum A, Herndon JE, Box J, Memoli V, Green MR, et al. Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer. 2001;33:115–123
  46. Brooks KR, To K, Joshi MB, Conlon DH, Herndon JE, D’Amico TA, et al. Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection. Ann Thorac Surg. 2003;76:187–193
  47. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res. 1995;55:5038–5042
  48. Sculier JP, Paesmans M, Lafitte JJ, Baumohl J, Thiriaux J, van Cutsem O, et al. A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. European Lung Cancer Working Party. Ann Oncol. 1999;10:295–303
  49. Sculier JP, Lafitte JJ, Berghmans T, van Houtte P, Lecomte J, Thiriaux J, et al. A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer. Ann Oncol. 2004;15:399–409
  50. Meert AP, Martin B, Verdebout JM, Paesmans M, Lothaire P, Bosschaerts T, et al. Corrélation entre l’expression d’EGFR dans les biopsies et les pièces chirurgicales des cancers bronchiques. Rev Mal Respir. 2003;20:347–353
  51. Meert AP, Martin B, Verdebout JM, Paesmans M, Berghmans T, Ninane V, et al. Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer. Lung Cancer. 2004;44:295–301

PII: S0169-5002(08)00063-9

doi: 10.1016/j.lungcan.2008.02.003

Lung Cancer
Volume 62, Issue 1 , Pages 35-44 , October 2008

Article Tools